Accession NumberDB06285
GroupsApproved, Investigational

Teriparatide (recombinant human parathyroid hormone) is a potent anabolic agent used in the treatment of osteoporosis. It is manufactured and marketed by Eli Lilly and Company.

Protein structureNo structure small
Related Articles
Protein chemical formulaC181H291N55O51S2
Protein average weight4117.715 Da
>Parathyroid hormone precursor - Homo sapiens (1-34)
Download FASTA Format
Teriparatide recombinant human
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Teriparatide acetate9959P4V12N 99294-94-7Not applicableDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ForteoSolution250 mcgSubcutaneousEli Lilly & Co. Ltd.2004-07-15Not applicableCanada
ForteoInjection, solution250 ug/mLSubcutaneousEli Lilly & Co. Ltd.2002-11-26Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
ForsteoEli Lilly and Company
Brand mixturesNot Available
CAS number52232-67-4

For the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. Also used to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.

Structured Indications

Clinical trials indicate that teriparatide increases predominantly trabecular bone in the lumbar spine and femoral neck; it has less significant effects at cortical sites. The combination of teriparatide with antiresorptive agents is not more effective than teriparatide monotherapy. The most common adverse effects associated with teriparatide include injection-site pain, nausea, headaches, leg cramps, and dizziness. After a maximum of two years of teriparatide therapy, the drug should be discontinued and antiresorptive therapy begun to maintain bone mineral density.

Mechanism of action

Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.

TargetKindPharmacological actionActionsOrganismUniProt ID
Parathyroid hormone/parathyroid hormone-related peptide receptorProteinunknown
HumanQ03431 details
Related Articles

Bioavailability is 95% following subcutaneous injection.

Volume of distribution
  • 0.12 L/kg
Protein bindingNot Available


Route of elimination

Peripheral metabolism of PTH is believed to occur by non-specific enzymatic mechanisms in the liver followed by excretion via the kidneys. The 24-hour urine excretion of calcium was reduced by a clinically unimportant amount (15%).

Half lifeNot Available
  • 62 L/hr [Women]
  • 94 L/hr [Men]

Effects of overexposure may include headaches, dizziness, dizziness, decreased blood pressured, decreased fetal survival, leg cramps, changes in clinical chemistry including increased in blood levels of calcium, decreased serum phosphorous, and increased urinary calcium and phosphorus.

Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Drug Interactions Not Available
Food InteractionsNot Available
Synthesis ReferenceNot Available
General References
  1. Stroup J, Kane MP, Abu-Baker AM: Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm. 2008 Mar 15;65(6):532-9. doi: 10.2146/ajhp070171. [PubMed:18319498 ]
  2. Close P, Neuprez A, Reginster JY: Developments in the pharmacotherapeutic management of osteoporosis. Expert Opin Pharmacother. 2006 Aug;7(12):1603-15. [PubMed:16872263 ]
External Links
ATC CodesH05AA02 — Teriparatide
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (24.4 KB)
Clinical Trials
Clinical Trials
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentBone Loss / Periodontitis1
1CompletedTreatmentDrug Safety1
1CompletedTreatmentOsteoporosis, Post-Menopausal1
1CompletedTreatmentPostmenopausal Osteoporosis (PMO)1
1CompletedTreatmentBone destruction1
1Enrolling by InvitationTreatmentDrug Safety and Bioavailability1
1Unknown StatusBasic ScienceBone destruction1
2Active Not RecruitingTreatmentAdult Idiopathic Generalized Osteoporosis1
2Active Not RecruitingTreatmentAnorexia Nervosa (AN) / Bone destruction1
2Active Not RecruitingTreatmentBone destruction / Bone Loss / Spinal Cord Injuries (SCI)2
2Active Not RecruitingTreatmentDiabetic Neuropathic Arthropathy1
2Active Not RecruitingTreatmentBone destruction2
2CompletedPreventionOsteoarthritis of the Knees1
2CompletedTreatmentColles' Fracture1
2CompletedTreatmentLow Bone Mineral Density / Postmenopausal Osteoporosis (PMO)1
2CompletedTreatmentPostmenopausal Osteoporosis (PMO)1
2CompletedTreatmentBone destruction8
2CompletedTreatmentParathyroid deficiency1
2Not Yet RecruitingTreatmentOsteoporotic Fractures1
2RecruitingTreatmentAutosomal Dominant Hypocalcemia / Autosomal Dominant Hypocalcemia or OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment1
2RecruitingTreatmentCartilage Degeneration / Osteoarthritis of the Knees1
2RecruitingTreatmentOsteogenesis Imperfecta1
2TerminatedPreventionAgnogenic Myeloid Metaplasia / Aplastic Anaemia (AA) / Hodgkins Disease (HD) / Leukemia, Lymphocytic, Acute / Leukemia, Lymphocytic, Chronic / Leukemia, Myelocytic, Acute / Leukemia,Myeloid, Chronic / Malignant Lymphomas1
2TerminatedTreatmentHypoparathyroidism Post-surgical1
2TerminatedTreatmentBone destruction1
2Unknown StatusTreatmentBone destruction / Osteopenia1
2WithdrawnTreatmentBone destruction / Osteopenia1
2WithdrawnTreatmentShoulder Fractures / Trochanteric Fractures1
2, 3Active Not RecruitingTreatmentBone destruction / Fracture Bone / Menopause1
2, 3CompletedTreatmentParathyroid deficiency1
3CompletedTreatmentBack Pain / Postmenopausal Osteoporosis (PMO) / Vertebral Fractures1
3CompletedTreatmentFemur Neck Fracture2
3CompletedTreatmentBone destruction / Osteopenia1
3CompletedTreatmentOsteoporosis, Post-Menopausal3
3CompletedTreatmentPostmenopausal Osteoporosis (PMO)4
3CompletedTreatmentBone destruction / Postmenopausal Osteoporosis (PMO)1
3CompletedTreatmentBone destruction10
3Not Yet RecruitingTreatmentUnstable Intertrochanteric Fracture1
3RecruitingTreatmentNon Displaced Atypical Femoral Fractures1
3RecruitingTreatmentBone destruction1
3Unknown StatusTreatmentLow Bone Mass in Anorexia Nervosa Patients1
3WithdrawnTreatmentHumeral Fractures / Osteoporosis, Age-Related1
4Active Not RecruitingTreatmentPostmenopausal Osteoporosis (PMO)1
4Active Not RecruitingTreatmentRheumatoid Arthritis1
4CompletedTreatmentAtypical Femoral Fractures / Bone destruction1
4CompletedTreatmentBone destruction / Bone Loss / Spinal Cord Injuries (SCI)1
4CompletedTreatmentHumeral Fractures1
4CompletedTreatmentOsteogenesis Imperfecta1
4CompletedTreatmentOsteoporosis, Post-Menopausal2
4CompletedTreatmentPostmenopausal Osteoporosis (PMO)7
4CompletedTreatmentBone destruction10
4RecruitingTreatmentFracture, Ankle1
4SuspendedTreatmentBone Marrow Oedema Syndrome / High Turnover Bone Disease / Quality of Life1
4TerminatedTreatmentBone destruction1
4Unknown StatusTreatmentFracture Bone1
4Unknown StatusTreatmentPostmenopausal Osteoporosis With Pathological Fracture1
4Unknown StatusTreatmentSpinal Stenosis1
Not AvailableActive Not RecruitingNot AvailableLow Bone Density1
Not AvailableActive Not RecruitingNot AvailableOsteoporosis, Steroid Induced / Postmenopausal Osteoporosis (PMO)1
Not AvailableActive Not RecruitingNot AvailableBone destruction1
Not AvailableCompletedNot AvailableBone destruction / Postmenopausal Osteoporosis (PMO)1
Not AvailableCompletedNot AvailableBone destruction4
Not AvailableCompletedDiagnosticHyperparathyroidism, Secondary1
Not AvailableRecruitingNot AvailableBone destruction1
Not AvailableRecruitingTreatmentAdult Degenerative Lumbar Scoliosis / Lumbar Spondylolisthesis / Lumbar Spondylosis1
Not AvailableRecruitingTreatmentKidney Failure,Chronic1
Not AvailableRecruitingTreatmentBone destruction1
Not AvailableTerminatedTreatmentFracture of Pelvis1
Not AvailableUnknown StatusTreatmentBone destruction1
Not AvailableWithdrawnTreatmentBone destruction1
ManufacturersNot Available
Dosage forms
Injection, solutionSubcutaneous250 ug/mL
SolutionSubcutaneous250 mcg
Unit descriptionCostUnit
Forteo 750 mcg/3 ml pen295.26USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2314313 No2005-02-082018-12-08Canada
CA2325371 No2004-08-172019-08-19Canada
US6770623 No1998-12-082018-12-08Us
US6977077 No1999-08-192019-08-19Us
US7144861 No1998-12-082018-12-08Us
US7163684 No1999-08-192019-08-19Us
US7351414 No1999-08-192019-08-19Us
US7517334 No2005-03-252025-03-25Us
US7550434 No1998-12-082018-12-08Us
Experimental PropertiesNot Available
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available


Pharmacological action
General Function:
Protein self-association
Specific Function:
This is a receptor for parathyroid hormone and for parathyroid hormone-related peptide. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and also a phosphatidylinositol-calcium second messenger system.
Gene Name:
Uniprot ID:
Uniprot Name:
Parathyroid hormone/parathyroid hormone-related peptide receptor
Molecular Weight:
66359.98 Da
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Drug created on March 19, 2008 10:21 / Updated on July 25, 2017 12:01